Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib
Author:
Publisher
Springer Science and Business Media LLC
Subject
Surgery
Link
http://link.springer.com/content/pdf/10.1007/s00423-014-1235-1.pdf
Reference60 articles.
1. Tj L, Dw B, Sordella R, Gurubhagavatula S, Ra O, Bw B, Pl H, Sm H, Jg S, Fg H, Dn L, Dc C, Settleman J, Da H (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
2. Cappuzzo F, Magrini E, Gl C, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Ct P, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133–1141
3. Cappuzzo F, Fr H, Rossi E, Bartolini S, Gl C, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Wa F, Crino L, Pa B Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655
4. Cohen M, Ga W, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303–306
5. Es K, Hirsh V, Mok T, Ma S, Gervais R, Yl W, Ly L, Cl W, Mv S, Es L, Sun Y, Ml L, Osterlind K, Reck M, Aa A, Fa S, Sm L, Jy D (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies;Onco;2023-07-15
2. Metastatic Esophageal Carcinoma Cells Exhibit Reduced Adhesion Strength and Enhanced Thermogenesis;Cells;2021-05-16
3. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?;Cancers;2020-10-22
4. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target;Journal of Enzyme Inhibition and Medicinal Chemistry;2018-01-01
5. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer;Journal of Clinical Oncology;2017-07-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3